X4 Pharmaceuticals Inc. Common Stock (XFOR)

About XFOR

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis s…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

45

Website

www.x4pharma.com/

Fundamentals

1-day range

$4.22$4.82

Market cap

$393.31M

P/E (trailing)

3.24

P/E (forward)

-6.38

EPS (trailing)

$-4.58

Dividend yield

—

Beta

0.42

Avg. volume

691.5K

Dividend pay date

March 14, 2019

Forecasts

5 analyst ratings

X4 Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• XFOR

  X4 Pharmaceuticals Inc. Common Stock

  $4.05

  ▼ 4.26%
  Market cap $393.31MP/E 3.24
  $2.8$4.83
• STRO

  Sutro Biopharma Inc. Common Stock

  $20.42

  ▼ 4.18%
  Market cap $400.18MP/E —
  $7.15$43.85
• FENC

  Fennec Pharmaceuticals Inc. Common Stock

  $12.19

  ▲ 3.57%
  Market cap $378.17MP/E —
  $5.65$13.25
• OCGN

  Ocugen Inc. Common Stock

  $1.32

  ▼ 3.65%
  Market cap $420.50MP/E —
  $1$2.73
• PALI

  Palisade Bio Inc. Common Stock

  $2.01

  ▼ 4.74%
  Market cap $362.78MP/E —
  $0.53$2.86
• LXEO

  Lexeo Therapeutics Inc. Common Stock

  $4.87

  ▼ 2.51%
  Market cap $357.27MP/E —
  $3.99$10.99
• IPSC

  Century Therapeutics Inc. Common Stock

  $2.03

  ▼ 9.19%
  Market cap $342.67MP/E —
  $0.435$3.04

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat Congenital
  benzinga · 8/26/2026
• X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)
  SeekingAlpha · 8/19/2026
• Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
  Benzinga · 8/10/2026
• X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate
  Benzinga · 8/6/2026

• John Volpone · August 12, 2026 · Sale

  24.6K @ $4.44
• Adam R. Craig · August 12, 2026 · Sale

  47.4K @ $4.44
• Kelly Gold · July 1, 2026 · Grant

  110.0K
• David Kirske · June 30, 2026 · Sale

  8.5K @ $4.26
• David Kirske · May 12, 2026 · Sale

  17.0K @ $4.29

Institutional Ownership

March 31, 2026

Total shares held

89.91M

Total value held

$371.50M

Institutional holders

78